RE:RE:Pfizer Pfizer is taking a deeper dive into Precision Medicine which follows Pfiser's CEO Chris Bishoff announcement in January 2024 that the company's oncology division plans to shift to biologic drugs as its main source of revenue, and away from small molecules, increasing the proportion of those biologic treatments from 6% to 65% by 2030. https://www.cnbc.com/2024/03/10/pfizer-is-betting-big-on-cancer-drugs-after-covid-decline.html Biologics are treatments derived from living sources such as animals or humans, including vaccines, stem cell treatments and gene therapies. They are among the most expensive prescription drugs in the U.S.
Before the Seagen deal, 94% of Pfizer’s cancer products were small-molecule drugs. Those medicines are made of chemicals and have low molecular weights.